These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 18537678)

  • 1. Natural compounds with proteasome inhibitory activity for cancer prevention and treatment.
    Yang H; Landis-Piwowar KR; Chen D; Milacic V; Dou QP
    Curr Protein Pept Sci; 2008 Jun; 9(3):227-39. PubMed ID: 18537678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the proteasome pathway.
    Tsukamoto S; Yokosawa H
    Expert Opin Ther Targets; 2009 May; 13(5):605-21. PubMed ID: 19397479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Proteasome inhibitor].
    Yamamura M; Hirai T; Yamaguchi Y
    Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The proteasome as a potential target for novel anticancer drugs and chemosensitizers.
    Landis-Piwowar KR; Milacic V; Chen D; Yang H; Zhao Y; Chan TH; Yan B; Dou QP
    Drug Resist Updat; 2006 Dec; 9(6):263-73. PubMed ID: 17197231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The proteasome: a novel target for anticancer therapy.
    Montagut C; Rovira A; Albanell J
    Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome: an emerging target for cancer therapy.
    Zavrski I; Jakob C; Schmid P; Krebbel H; Kaiser M; Fleissner C; Rosche M; Possinger K; Sezer O
    Anticancer Drugs; 2005 Jun; 16(5):475-81. PubMed ID: 15846112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
    Chen D; Frezza M; Schmitt S; Kanwar J; Dou QP
    Curr Cancer Drug Targets; 2011 Mar; 11(3):239-53. PubMed ID: 21247388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib: a novel therapy approved for multiple myeloma.
    Richardson PG; Anderson KC
    Clin Adv Hematol Oncol; 2003 Oct; 1(10):596-600. PubMed ID: 16258456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the ubiquitin-proteasome pathway: an emerging concept in cancer therapy.
    Frezza M; Schmitt S; Dou QP
    Curr Top Med Chem; 2011 Dec; 11(23):2888-905. PubMed ID: 21824109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel proteasome inhibitors to overcome bortezomib resistance.
    Ruschak AM; Slassi M; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2011 Jul; 103(13):1007-17. PubMed ID: 21606441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential for proteasome inhibition in the treatment of cancer.
    Adams J
    Drug Discov Today; 2003 Apr; 8(7):307-15. PubMed ID: 12654543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of the proteasome inhibitor Velcade (Bortezomib).
    Adams J; Kauffman M
    Cancer Invest; 2004; 22(2):304-11. PubMed ID: 15199612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrocyclic proteasome inhibitors.
    Krahn D; Ottmann C; Kaiser M
    Curr Med Chem; 2011; 18(33):5052-60. PubMed ID: 22050753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.
    Cheriyath V; Jacobs BS; Hussein MA
    Drugs R D; 2007; 8(1):1-12. PubMed ID: 17249845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib.
    Cvek B; Dvorak Z
    Curr Pharm Des; 2011; 17(15):1483-99. PubMed ID: 21504411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ubiquitin and cancer: from molecular targets and mechanisms to the clinic -- AACR Special Conference.
    Colland F
    IDrugs; 2006 Mar; 9(3):179-81. PubMed ID: 16523381
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug discovery and assay development in the ubiquitin-proteasome system.
    Berkers CR; Ovaa H
    Biochem Soc Trans; 2010 Feb; 38(Pt 1):14-20. PubMed ID: 20074028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altering protein turnover in tumor cells: new opportunities for anti-cancer therapies.
    Demarchi F; Brancolini C
    Drug Resist Updat; 2005 Dec; 8(6):359-68. PubMed ID: 16406769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-angiogenic and anti-tumor properties of proteasome inhibitors.
    Daniel KG; Kuhn DJ; Kazi A; Dou QP
    Curr Cancer Drug Targets; 2005 Nov; 5(7):529-41. PubMed ID: 16305349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
    Mitsiades CS; Mitsiades N; Hideshima T; Richardson PG; Anderson KC
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):465-76. PubMed ID: 16001954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.